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Abstract
Background—Community-acquired pneumonia (CAP) is a leading cause of pediatric 
hospitalization. Pathogen identification fails in approximately 20% of children but is critical for 
optimal treatment and prevention of hospital-acquired infections. We used two broad-spectrum 
detection strategies to identify pathogens in test-negative children with CAP and asymptomatic 
controls.
Methods—Nasopharyngeal/oropharyngeal (NP/OP) swabs from 70 children <5 years with CAP 
of unknown etiology and 90 asymptomatic controls were tested by next-generation sequencing 
(RNA-seq) and pan viral group (PVG) PCR for 19 viral families. Association of viruses with CAP 
was assessed by adjusted odds ratios (aOR) and 95% confidence intervals controlling for season 
and age group.
Results—RNA-seq/PVG PCR detected previously missed, putative pathogens in 34% of 
patients. Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human 
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bocavirus (aOR 9.1, P < .01), Coxsackieviruses (aOR 5.1, P = .09), rhinovirus A (aOR 3.5, P = .
34), and rhinovirus C (aOR 2.9, P = .57). RNA-seq was more sensitive for RNA viruses whereas 
PVG PCR detected more DNA viruses.
Conclusions—RNA-seq and PVG PCR identified additional viruses, some known to be 
pathogenic, in NP/OP specimens from one-third of children hospitalized with CAP without a 
previously identified etiology. Both broad-range methods could be useful tools in future 
epidemiologic and diagnostic studies.
Keywords
RNA sequencing (RNA-seq); metagenomics; pan-viral group polymerase chain reaction (PVG 
PCR); pneumonia
Pneumonia is a leading cause of childhood death globally; approximately 1 million children 
die of pneumonia every year [1]. In the United States, up to 50% of children aged ≤5 years 
with community-acquired pneumonia (CAP) require hospitalization, accounting for 110 000 
admissions annually [2]. Pathogens vary by age [3–5], but viruses are the most common 
cause of CAP in children aged ≤5 years, especially in the absence of lobar pneumonia and 
pleural effusion [3]. However, a pathogen cannot be identified in 14%–23% of children with 
CAP, even with extensive testing [4–11]. More effective pathogen identification will 
improve our understanding of pneumonia and guide treatment and site-of-care decisions.
Inability to detect etiologic agents may be due to incomplete test panels, genetic pathogen 
variants escaping molecular detection, unrecognized bacterial infections due to insensitive 
diagnostics, novel and emerging pathogens, or inadequate specimens. Most of these 
limitations could be overcome by unbiased pathogen detection [12, 13]. Shotgun 
metagenomic sequencing of DNA or RNA (RNA sequencing [RNA-seq]) and broad-range 
polymerase chain reaction (PCR) amplification of conserved pathogen genomic regions are 
two such methods. RNA sequencing enables sequence-independent detection of any 
pathogen with sufficient sequence homology to known viruses, bacteria, fungi, or parasites 
to allow their classification [13–15]. Panviral group (PVG) PCR uses broad-range PCR 
primers to detect known and novel members of relevant viral genera and families [16].
The aim of this study was to identify potential pathogens in children enrolled in a 
multicenter study of children hospitalized with CAP but without identifiable diagnosis after 
extensive testing [4].
METHODS
Study Population
Participants were children enrolled in the US Centers for Disease Control and Prevention 
Etiology of Pneumonia in the Community (EPIC) study. The EPIC study population, 
enrollment criteria, specimen collection, and etiologic testing have been described in detail 
[4]. Patients were included if they lived in the catchment area and were hospitalized for 
CAP, defined as acute infection, acute respiratory illness, and radio-graphically confirmed 
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pneumonia. Exclusion criteria included recent hospitalization and severe 
immunosuppression.
For this analysis (University of Utah IRB 35409, CDC IRB 5827), we included children (n = 
70) with CAP and asymptomatic pediatric control subjects aged <5 years enrolled at Primary 
Children’s Hospital in Salt Lake City, Utah (Table 1). Patients were enrolled between 1 
January 2010 and 30 June 2012. Control subjects (n = 90) were same-day elective surgery 
patients and were enrolled between 1 February 2011 and 30 June 2012; if a control subject 
had respiratory symptoms or fever within 14 days of enrollment, they were excluded. 
Patients and control subjects were included if no pathogen was detected per EPIC study 
protocol [4].
Specimen Collection and Pathogen Detection in the EPIC Study
For children hospitalized with CAP, combined nasopharyngeal (NP) and oropharyngeal (OP) 
swabs were collected within 72 hours of hospital admission. Specimens were transferred 
into 3-mL universal transport media, refrigerated, and stored at −80°C within 24 hours. 
Bacteria (Haemophilus influenzae or other Gram-negative bacteria, Staphylococcus aureus, 
Streptococcus anginosus, Streptococcus mitis, Streptococcus pneumoniae, or Streptococcus 
pyogenes) were detected by culture (blood, endotracheal aspirate, bronchoalveolar-lavage 
specimen, pleural fluid) or PCR (whole blood, pleural fluid); Chlamydophila pneumoniae 
and Mycoplasma pneumoniae were detected by PCR from NP/OP swabs. Viruses 
(adenovirus [ADV], coronavirus, human metapneumovirus, human rhinovirus [HRV], 
human influenza, parainfluenza viruses 1–3 [HPIV], and respiratory syncytial virus) were 
detected by PCR of NP/OP swabs or serology of acute-and convalescent-phase serum 
(except for human rhinovirus and coronaviruses) [4]. Nasopharyngeal and OP swabs were 
also obtained from asymptomatic control subjects before elective surgery while in the 
operating room and tested for viral pathogens, C. pneumoniae, and M. pneumoniae [4].
RNA Sequencing
Nucleic Acid Extraction—Nasopharyngeal and OP swabs (75–200 µL) were extracted 
using the QIAamp Viral RNA extraction kit per manufacturer’s instructions with the 
addition of on-column DNase treatment after AW1 wash (10 µL of RNase-free DNase I plus 
70 µL of Buffer RDD, Qiagen) at room temperature for 15 minutes and an additional wash 
step.
Library Generation—Indexed cDNA libraries were prepared with the TruSeq RNA 
Sample Prep Kit following manufacturer’s instructions (Illumina). Libraries were quantified 
with the Illumina Universal Library Quantification Kit (Kapa Biosystems) and the Applied 
Biosystems 7900HT Fast Real-Time PCR System (Applied Biosciences). Library size and 
quality was assessed with a High Sensitivity DNA Analysis Kit on an Agilent 2100 
Bioanalyzer (Agilent Technologies). Libraries from 24 samples were combined in equimolar 
ratios for a final concentration of 9.6 nM and sequenced in batches of 24 samples per lane on 
a HiSeq 2500 instrument (Illumina), generating an average of 1.7 × 107 sequencing reads (2 
× 100 base pairs) per sample.
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Analysis of Metagenomics Data—Matching paired-end reads were concatenated, 
adding an “N” between read 1 and read 2. The resulting sequences were analyzed by 
Taxonomer [14], an alignment-free, rapid, interactive metagenomic sequence analysis tool 
for microbial identification and results visualized through http://taxonomer.iobio.io. Taxa 
with only 1 read assigned to them were ignored. Viral taxa (other than phages) were 
confirmed manually by mapping the sequencing files against the relevant reference 
sequences in Geneious (version 8.1, Biomatters) and by comparing viral sequences to the 
National Center for Biotechnology Information nucleotide database [17, 18]. Viral taxa 
identified based on <100 reads were only considered if reads were not an identical match to 
any other sample within the same batch by manual analysis. These protocols had previously 
been shown to produce results comparable with a US Food and Drug Administration–
cleared PCR panel [15].
Pan-Viral Group Family/Genus Polymerase Chain Reaction Panel
Nucleic Acid Extraction—Combined NP/OP swab samples (200 µL) in universal 
transport media were extracted using either a manual method by the QIAamp Viral RNA 
extraction kit (Qiagen) or an automated method by the BioSprint 96 One For All kit 
(Qiagen) on a Kingfisher 96 platform (Thermo) according to the manufacturer’s instructions.
Pan-Viral Goup Polymerase Chain Reaction—Pan-viral group PCR assays were 
designed to amplify known and potentially novel members of the viral families/genera listed 
below. They were designed using the consensus-degenerate hybrid oligonucleotide primer 
(CODEHOP) principle to conserved genes and regions [19, 20] and had analytical 
sensitivities of 10–500 copies (RNA viruses) and 10–1000 copies (DNA viruses) per 
reaction. Samples (5 µl of total nucleic acid) were tested with broadly reactive PVG PCR for 
the following viral families/genera: Adenoviridae, Anelloviridae, Arenaviridae, Astroviridae, 
Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae (Flavivirus), 
Herpesviridae, Orthomyxoviridae (influenza viruses A, B, and C), Paramyxoviridae, 
Parvoviridae, Picornaviridae (enterovirus and parechovirus; primers do not target all human 
rhinoviruses), Polyomaviridae, Reoviridae (aquareovirus, orthoreovirus, orbivirus, rotavirus, 
and seadornavirus), Rhabdoviridae, and Togaviridae (alphavirus) [21–28]. The 
Picornaviridae PCR targets only a subset of human rhinoviruses. First-round reverse-
transcription PCR for RNA viruses was performed with Superscript III/Platinum Taq One 
Step kits (Invitrogen), and second-round PCR was performed with Titanium Taq (Clontech) 
kits. First- and second-round PCR for DNA viruses was performed with Hot Start Ex Taq 
kits (Takara). Positive and negative PCR controls containing mutation-engineered synthetic 
RNA transcript or DNA amplicon and nuclease-free water, respectively, were included in 
each run. Polymerase chain reaction products were visualized on 2% agarose gels.
Sequence Confirmation—Positive bands of the expected size that had strong signal and 
without additional bands were cleaned up using Exonuclease I (New England Biolabs) and 
Shrimp Alkaline Phosphatase (Roche). Samples were incubated at 37°C for 15 minutes 
followed by 80°C for 15 minutes to inactivate the Exonuclease and Shrimp Alkaline 
Phosphatase. Positive bands of the expected size with additional bands present in the PCR 
products were purified using QIAquick Gel Extraction kits (Qiagen). Purified PCR 
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amplicons were sequenced with the PCR primers in both directions on an ABI Prism 3130 
Automated Capillary Sequencer (Applied Biosystems) using Big Dye 3.1 cycle sequencing 
kits (Life Technologies).
Validation
We first assessed the ability of RNA-seq and PVG PCR to detect known respiratory 
pathogens using specimens from children with CAP (n = 63) and asymptomatic control (n = 
52) subjects in whom viral or atypical bacterial pathogens had been detected using the EPIC 
study protocol. Nasopharyngeal and OP specimens were analyzed by RNA-seq and PVG 
PCR as described.
Statistics
Proportions of putative pathogens detected by each method individually or in combination 
were determined. Descriptive statistics were calculated, and proportions were compared by 
χ2 or Fisher exact test, as appropriate. To assess the association of virus detection with 
disease, we compared children with CAP with asymptomatic control subjects and calculated 
adjusted odds ratios (aORs) and 95% confidence intervals (CIs) using approximate exact 
logistic regression controlling for season and age group. All statistical analyses were 
performed with a 2-tailed α of .05 using R 3.2.2 (R Foundation for Statistical Computing). 
Approximate exact logistic regression models were developed using the elrm package for R 
with 1 000 000 Markov chain iterations and 20 000 burn-in iterations that were discarded 
when conducting the inference.
RESULTS
Validation of Respiratory Pathogen Detection by RNA Sequencing and Pan-Viral Group 
Polymerase Chain Reaction
We validated RNA-seq and PVG PCR methods to detect known respiratory pathogens by 
testing specimens using both methods from children with CAP (n = 63) and asymptomatic 
control subjects (n = 52) in whom viral or atypical bacterial pathogens had been detected 
using the EPIC study protocol. In children with pneumonia, RNA-seq detected 90% of 
pathogens detected by the EPIC study tests, and PVG PCR detected 57% (78% when 
excluding HRV and M. pneumoniae) (Table 2). In control subjects, the proportion detected 
was 64% by RNA-seq and 22% by PVG PCR (38% when excluding HRV) ( Table 2). 
Combining results of both methods, 93% of known pathogens in patients and 73% of known 
pathogens in control subjects were detected. Table 2 shows sensitivity and specificity for 
detection of each of the known pathogens. Calculations were based only on the tested 
samples. Results could be different when calculated for the entire EPIC study. A trend 
toward lower sensitivity in control subjects may be related to lower viral loads in 
asymptomatic children [29–34]. Of note, sensitivity was lowest for adenovirus for both 
methods; RNA-seq did not detect any of the 8 ADV-positive samples (n = 3 patients; n = 5 
control subjects), whereas PVG PCR detected ADV in 1 of 3 patients and 3 of 5 control 
subjects. RNA sequencing detected HRV in 46 (92%) of 50 PCR-positive specimens, 
whereas PVG PCR detected 7 (14%) of 50. All M. pneumoniae infections were detected by 
RNA-seq but not targeted by PVG PCR.
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Detection of Additional, Previously Unrecognized Respiratory Pathogens in Validation 
Samples by RNA Sequencing and Pan-Viral Group Polymerase Chain Reaction
From these specimens in which pathogens were detected by PCR, RNA-seq and PVG PCR 
detected 58 previously unrecognized viruses in 63 children with CAP and 61 previously 
unrecognized viruses in 52 asymptomatic control subjects (Figure 1). Anelloviruses were the 
most commonly detected viruses (n = 34 patients; n = 38 control subjects), followed by 
human herpesvirus 6 (HHV6; n = 8 patients; n = 9 control subjects), and human herpesvirus 
7 (HHV7; n = 6 patients; n = 10 control subjects). Other viruses of interest were human 
bocavirus (HBoV; n = 4 patients; n = 1 control subject), astrovirus (n = 3 patients; n = 0 
control subjects), human parechovirus (n = 1 patient; n = 1 control subject), and measles 
virus (n = 1 patient).
Pathogen Detection in Previously Test-Negative Specimens by RNA Sequencing and Pan-
Viral Group Polymerase Chain Reaction
Human viruses were detected in 53 of 70 (76%) children with pneumonia and 55 of 90 
(61%) control subjects (Figure 2, Table 3) who were test-negative using the EPIC study 
protocol. In patients compared with control subjects, the most commonly detected viruses 
were anelloviruses (49% vs 36%; aOR = 1.6; 95% CI = .7–3.5), HHV6 (13% vs 10%; aOR 
= 1.0; 95% CI = .3–3.3), and HHV7 (9% vs 10%; aOR = 1.2; 95% CI = .3–4.4). Human 
bocavirus was detected in a significantly greater proportion of patients (18.6%) than control 
subjects (2.2%; aOR = 9; 95% CI = 1.6–102.9; P < .01). Coxsackieviruses were detected in 
3 patients (4.3%) and no control subjects, but this association was not statistically significant 
(aOR = 5.1; 95% CI = 0.5–∞; P = .09). Other potential pathogens were more commonly 
detected in patients than control subjects, but these differences were not statistically 
significant: HRV-A (aOR = 3.5; 95% CI = .2–199; P = .34), and HPIV-4 (aOR = 9.3; 95% 
CI = .4–741; P = .12). Additional viruses detected included Epstein-Barr virus (n = 4 
patients; n = 2 control subjects), measles virus (n = 2 patients), polyomaviruses (n = 2 
patients), HPV type 5 (n = 1 patient), herpes simplex virus (n = 1 patient), rotavirus (n = 1 
patient), parvovirus B19 (n = 1 patient; n = 1 control subject), and echovirus (n = 1 control 
subject). Cytomegalovirus (CMV; n = 1 patient; n = 3 control subjects), human parechovirus 
(n = 1 patient; n = 3 control subjects), and cardioviruses (n = 2 control subjects) were more 
commonly detected in control subjects than in patients. Figure 3 shows the proportion of 
codetected putative pathogens; 24% of detections in patients and 22% of detections in 
control subjects were codetections. Monodetection of HBoV was significantly associated 
with CAP (OR = 7.3; 95% CI = 1.6–35).
Comparison of Viral Detection by RNA Sequencing and Pan-Viral Group Polymerase Chain 
Reaction
In children with CAP with no identifiable etiology, 32% of all viruses were detected by both 
methods, 22% by RNA-seq only and 47% by PVG PCR only (Supplementary Figure 1). In 
control subjects, 19% of all viruses were detected by both methods, 20% by RNA-seq only, 
and 61% by PVG PCR only. The vast majority of viruses only detected by PVG PCR were 
anelloviruses, HHV6, and HHV7, which, combined, were detected in 35 of 41 (85%) 
patients and 37 of 39 (95%) control subjects (Supplementary Figure 1). In patients, the 
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remaining viruses were most commonly detected by both methods (46%) or by RNA-seq 
only (38%; compared with 15% by PVG PCR only). In control subjects, the remaining 
viruses were more frequently detected by RNA-seq (64%) than by both methods (21%) or 
by PVG PCR only (14%). In 2 RNA-seq–positive/PVG PCR–negative samples, the entire 
viral genome could be determined. Two and 1 mismatches were identified in reverse primer 
binding sites of these Coxsackievirus and HRV-C genomes, respectively. Failure to detect 
these 2 viruses by PGV PCR was more likely due to reduced sensitivity of degenerate PCR 
primers than primer mismatches.
Bacteria in Children With Pneumonia With No Identifiable Etiology
One infant with CAP and no identified pathogen by the EPIC study protocol had C. 
trachomatis detected by RNA-seq. In 2 patients with CAP, a potential bacterial pathogen was 
identified (Figure 4). Although a diverse set of bacteria consistent with upper respiratory 
tract flora was detected in most patients, the flora in these 2 patients was dominated by a 
single Gramnegative organism. In a 23-month-old patient with trisomy 21, Pseudomonas 
fluorescens dominated the bacterial sequences (approximately 95%, best matching strain 
LBUM223, accession number CP_011117). In a 10-month-old patient with spina bifida, 
chiari malformation, and history of aspiration pneumonia, approximately 90% of bacterial 
sequences originated from Serratia marcescens (best matching strain FGI94, accession 
number NC_020064).
DISCUSSION
Using RNA-seq and PVG PCR, we identified additional viruses from upper respiratory tract 
specimens in >30% children hospitalized with clinical and radiographic pneumonia but in 
whom no pathogen was identified despite extensive testing by culture, molecular, and 
serologic methods. Human bocavirus, Coxsackieviruses, HPIV-4, HRV-C, and HRV-A were 
more commonly detected in children with CAP compared with control subjects, but only 
HBoV was statistically more common than in control subjects. This suggests that these 
pathogens may have played an etiologic role in CAP. Making an etiologic diagnosis in 
patients with pneumonia is important for understanding the epidemiology, providing 
appropriate therapy, and limiting unnecessary use of antimicrobials. However, extensive 
testing using standard approaches is unable to identify a pathogen in approximately 20% of 
children and approximately 60% of adults [4, 35]. Data from our proof-of-concept study of 
upper respiratory specimens suggest that RNA-seq and PVG PCR enable more 
comprehensive pathogen detection compared with virus-specific, real-time PCR-based tests. 
Although specimens from the upper respiratory tract can be collected without invasive 
procedure, they are most useful for identifying viral infections and have limited utility in 
testing for bacterial pneumonia.
The detected viruses in our study can be broadly categorized into 4 groups: (1) known 
respiratory pathogens, (2) viruses of unclear pathogenicity, (3) opportunistic viruses that are 
pathogenic in immunocompromised hosts, and (4) viruses not thought to play a pathogenic 
role in respiratory tract illness. Among known respiratory pathogens, we detected 
Coxsackievirus, HRV, ADV, HPIV, human parechovirus, and measles virus, which, 
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combined, were detected in 33% of children with CAP. Coxsackievirus, HRV, ADV, HPIV, 
and measles virus were all more commonly detected in patients than control subjects (aOR > 
2), but possibly due to the overall low frequency of these detections, these differences did 
not reach statistical significance. Human parechovirus and echovirus can cause respiratory 
tract infections but were detected infrequently in both patients and control subjects (aOR = 
1.3 and 0.4, respectively). The 2 patients with measles virus detection did not show signs of 
measles but had been vaccinated 7 days (positive by RNA-seq only) and 9 days (positive by 
RNA-seq and PVG PCR) before sample collection, suggesting we detected vaccine strain. 
However, the low number of sequencing reads precluded demonstrating this by examining 
the complete viral genome. Cardioviruses, which are a possible cause of respiratory tract 
infections [36], were only detected in control subjects and not patients.
Human bocavirus was the most commonly detected virus among children with CAP and no 
identified pathogen (n = 13/70; 19%). Human bocavirus detection was strongly associated 
with CAP (aOR = 9.1; 95% CI = 1.6–103) (Figure 2). Three of these infections (23%) were 
codetections with other putative viral pathogens, and monodetection of HBoV was 
significantly associated with CAP (OR = 7.3; 95% CI = 1.6–35). Human bocavirus was not 
targeted as part of the EPIC study protocol due to uncertainty over its role as a human 
pathogen [37, 38]. Human bocavirus is a Parvovirus with a DNA genome and can be 
detected for weeks to months following acute infections, which makes it difficult to 
demonstrate its pathogenicity even in well-designed epidemiologic studies. Pan-viral group 
PCR detected HBoV DNA in 12 of 70 patients (17.1%) and 2 of 90 asymptomatic control 
subjects (2.2%). RNA sequencing identified HBoV mRNA in 10 of 70 patients (14.3%) and 
0 of 90 asymptomatic control subjects (aOR = 31.4; 95% CI = 1.8– 546; P < .05). 
Sequencing reads spanning splice sites of the viral capsid mRNA [39] confirmed that mRNA 
rather than genomic DNA served as the sequencing template (data not shown). This strong 
association is in contrast with numerous PCR-based studies targeting viral genomic DNA 
[37, 40], suggesting that detection of HBoV mRNA may serve as a marker for acute (ie, 
clinically relevant) infections. Although these results will need to be confirmed in larger 
studies, our results suggest that HBoV may be associated with CAP and may be a true 
pathogen.
Human herpesviruses that can cause respiratory tract infections including pneumonia in 
immunocompromised hosts (eg, HSV, CMV, parvovirus B19, HHV6) were more frequently 
detected in patients than control subjects in our analysis. However, children with severely 
immune-compromising conditions were excluded from the EPIC study. These viruses were 
more frequently detected by PVG PCR (targeting viral genomic DNA) than by RNA-seq. In 
the absence of detectable RNA, active replication is unlikely, and their detection may be a 
result of reactivation or latent infection rather than acute infection. Lastly, we detected a 
number of viruses not known to cause respiratory tract infections, including EBV, 
anelloviruses, HHV7, polyomaviruses, and papillomavirus. Their detection in the 
nasopharynx and/or oropharynx of asymptomatic children as well as CAP patients (in 
validation and test-negative groups) is consistent with previous reports [41–47]. Their 
detection demonstrates both the power of comprehensive pathogen detection but also the 
importance of using appropriate controls. Interestingly, detection rates for these DNA 
viruses were much higher by DNA-based PVG PCR than by RNA-seq. It is possible that 
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RNA-based testing may be more sensitive for DNA viruses during high-level replication 
when mRNA is abundant.
Although both RNA-seq and PVG PCR provide broad-range detection of respiratory viruses, 
each method has potential advantages and disadvantages. RNA sequencing is highly 
unbiased, demonstrated by the detection of divergent enteroviruses not identified by PVG 
PCR, and enables identification of nonviral pathogens, as exemplified by detection of M. 
pneumoniae and C. trachomatis. In contrast, PVG PCR identified DNA viruses that were not 
detected by RNA-seq. This may have been due in part to shedding predominantly of viral 
particles (containing genomic DNA) with low levels of active replication (ie, production of 
mRNA) in the upper respiratory tract. Performing next-generation sequencing with both 
RNA-seq and DNA sequencing might increase the yield for DNA viruses and bacteria but at 
increased financial cost.
As hypothesized, broad-range pathogen detection enabled identification of viruses not part 
of comprehensive test panels (eg, HBoV, Coxsackievirus, HPIV-4, Echovirus, human 
parechovirus), genetically divergent strains escaping PCR-based detection (as can be seen 
with genetically diverse viruses; eg, HRV-A, HRV-C), and unrecognized bacterial infections 
(eg, C. trachomatis) [15]. In addition to the sequence data analysis described above, we also 
performed de novo assembly of RNA-seq results and searched resulting contiguous 
sequences for conserved protein profiles [48] on all data from children with CAP without 
identifying additional putative pathogens (data not shown). Despite these extensive efforts, a 
potential pathogen was still not detected in 46 children (65.7%) with CAP of unknown 
etiology. This could have been due to testing of NP/OP swabs and not lower respiratory tract 
samples, which are preferred for detection of bacterial and fungal pathogens; focus on viral 
pathogens; inadequate timing of sample collection; polymicrobial infections caused by 
bacterial or fungal pathogens; or noninfectious mimics. Use of broad-range methods may 
provide even greater benefits in the 60% of adults with CAP in whom no pathogen is 
detected using conventional approaches [35]. Our findings also highlight the limits of 
etiologic diagnosis of CAP with noninvasive samples. We cannot exclude that highly diverse 
viruses without homology to known human viral pathogens may have caused CAP in some 
of the children. Further advancing the diagnosis of CAP is likely to require additional 
sampling as well as host-based markers of infectious processes that may help confirm 
infectious etiologies even when a pathogen cannot be directly detected [49].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Detection of additional human viruses by RNA sequencing (RNA-seq) and pan-viral group 
polymerase chain reaction (PVG PCR) in children with community-acquired pneumonia (n 
= 63) and control subjects (n = 52) with positive pathogen-specific tests using the Etiology 
of Pneumonia in the Community (EPIC) study protocol. Human viruses detected by RNA-
seq and PVG PCR that were not targeted in EPIC included human parechovirus, human 
bocavirus, Ebstein-Barr virus, human herpesvirus 6, and human herpesvirus 7. 
Abbreviatons: EBV, Epstein-Barr virus; HBoV, human bocavirus; HHV6, human 
herpesvirus 6; HHV7, human herpesvirus 7; HPeV, human parechovirus; PVG PCR, pan-
viral group polymerase chain reaction; RNA-seq, RNA sequencing.
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Figure 2. 
Viruses detected by RNA sequencing and/or pan-viral group polymerase chain reaction in 
children with pneumonia with no identifiable etiology (n = 70; red) and asymptomatic 
control subjects (n = 90; blue). A total of 20 different human viruses were detected in 
nasopharyngeal/oropharyngeal samples. In addition, Chlamydia trachomatis was detected in 
1 newborn child with pneumonia. Fifteen viruses were more frequently detected in patients 
than control subjects (odds ratios >1), with human bocavirus (P < .001) having significant 
associations with community-acquired pneumonia. Abbreviations: ADV, adenovirus; aOR, 
adjusted odds ratio (adjusted for season and age group); C. trachomatis, Chlamydia 
trachomatis; CI, confidence interval; CMV, cytomegalovirus; HBoV, human bocavirus; 
HHV6, human herpesvirus 6; HHV7, human herpesvirus 7; HPeV, human parechovirus; 
HPIV-4, human parainfluenza virus type 4; HRV-A, human rhinovirus A; HRV-C, human 
rhinovirus C; HSV, herpes simplex virus; OR, odds ratio.
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Figure 3. 
Putative pathogens by RNA sequencing and/or pan-viral group polymerase chain reaction in 
children with pneumonia with no identifiable etiology (n = 70; red) and asymptomatic 
control subjects (n = 90; blue). In 31% of detections, other putative pathogens were 
codetected (hashed bars), whereas no other putative pathogen was detected in the remaining 
samples (monodetection). Odds ratios (ORs) and 95% confidence intervals (CIs) are shown. 
Only monodetection of human bocavirus was significantly associated with community-
acquired pneumonia. Abbreviations: HBoV, human bocavirus; HPeV, human parechovirus 
HPIV-4, human parainfluenza virus type 4; HRV-A, human rhinovirus A; HRV-C, human 
rhinovirus C.
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Figure 4. 
An abundant bacterial flora (>95% of sequencing reads) dominated by a single potential 
pathogen was detected by RNA sequencing in nasopharyngeal/oropharyngeal (NP/OP) 
samples of 2 children with community-acquired pneumonia and no identified pathogen by 
the Etiology of Pneumonia in the Community study protocol. A, In a 23-month-old patient, 
94.6% of sequencing reads generated from the NP/OP sample was identified as 
Pseudomonas fluorescens, covering 35% of the genome of strain LBUM223 (NCBI 
accession number CP_011117) at a mean of 332X (data analyzed as described in [14]). B, In 
a 10-month-old patient, 89.7% of sequencing reads were derived from Serratia marcescens, 
covering 1.5% of the genome sequence of strain FGI94 (NCBI accession number 
NC_020064) at a mean of 537X.
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Table 1
Demographic and Clinical Information of Children With Pneumonia With No Identifiable Etiology and 
Control Subjects
Patients
(n = 70)
Control subjects
(n = 90) P value (χ2)
Age group, no. (%) .05
    <1 y 14 (20) 23 (26)
    1 y 26 (37) 18 (20)
    2–4 y 30 (43) 49 (54)
Month of enrollment, no. (%) .04
    January–March 23 (33) 13 (14)
    April–June 25 (36) 37 (41)
    July–September 16 (23) 25 (28)
    October–December 6 (9) 15 (17)
Symptom, no. (%) NA
    Fever 67 (96) NA
    Cough 58 (83) NA
    Anorexia 53 (76) NA
    Dyspnea 33 (47) NA
Underlying condition, no. (%) ns
    Asthma or reactive airway disease 6 (9) 3 (3)
    Preterm birth among children aged <2 y 7 (10) 7 (8)
Radiographic findings, no. (%) NA
    Consolidation 32 (45) NA
    Alveolar or interstitial infiltrate 23 (33) NA
    Pleural effusion 20 (29) NA
Hospitalization NA
    Length of stay, median (IQR) 3 (2–4) NA
    ICU admission, no. (%) 19 (27) NA
    Death in the hospital, no. (%) 0 (0) NA
Abbreviations: ICU, intensive care unit; IQR, interquartile range; NA, not applicable; NS, not significant.
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Table 3
Putative Pathogens Detected in Children with Community-Acquired Pneumonia of Unknown Etiology by 
RNA Sequencing or Pan-Viral Group Polymerase Chain Reaction
Patients
Putative pathogen No. %
Chlamydia trachomatis 1 1.4
Coxsackievirus A6 1 1.4
Coxsackievirus A6 and human bocavirus 1 1.4
Coxsackievirus B3 1 1.4
Human bocavirus 10 14.3
Human parainfluenza virus 4 2 2.9
Human parechovirus 1 1.4
Human rhinovirus A 1 1.4
Human rhinovirus A and human bocavirus 2 2.9
Human rhinovirus C 2 2.9
None 48 65.7
Total 70 100
A putative pathogen was detected in 24 of 70 children (34.3%).
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